Skip to content

Recovery & Aftercare

Hair-transplant recovery is unusual because the cosmetic result gets worse before it gets better. Crusts and redness dominate the first two weeks. Then the transplanted shafts fall out — 70–100% of them — at roughly 2–6 weeks. A 2–4 month dormancy follows. Regrowth begins around month 3, the bulk of grafts are visible by month 6–9, and final density is judged at 12–18 months.

The headline date isn't "when can I go back to work" (most people: ~day 5). It's "when do I see what I paid for" — and that's nearly a year out.

Shedding is not failure

Between weeks 2 and 6, the transplanted hair shafts will fall out. This panics nearly everyone going through it for the first time. The follicle bulb survives in the recipient site; only the existing shaft is shed because surgical trauma forced the follicle from anagen into telogen. New growth emerges from those same follicles starting around month 3. If your grafts are shedding on schedule, your transplant is doing exactly what it should.

This page covers the post-op course only. For who's a candidate and when to operate, see Candidacy & Timing. For how this compares to a scalp advancement recovery, see Hairline Advancement → Recovery.

The big-picture timeline

Phase What's happening
Days 0–14 Crusts at every graft, edema migrates down to eyelids day 2–4, donor wound healing. Grafts fragile until ~day 9. Most people back at desk work by day 5.
Weeks 2–8 Shock loss: 70–100% of transplanted shafts shed. Recipient zone often looks thinner than pre-op, especially if native shock loss also occurred.
Months 2–6 Dormancy then early regrowth. First "spiky" terminal hairs at month 3; ~50% of grafts visible by month 6. Texture wiry/curly initially.
Months 6–12 Density and caliber build steadily. ~85–95% of final result by month 12.
Months 12–18 Caliber, color, and curl pattern mature. Final cosmetic assessment. Revision/touch-up grafting (if needed) is timed here.

These windows are pooled from cis-male AGA cohorts plus smaller cis-female and transfeminine series. Individual variation is wide. Coarse, curly, dark hair gives apparent density faster than fine, straight, light hair at any given month.

Day-by-day for the first two weeks

Four phenomena overlap in the early course: crust formation at every recipient site, edema that migrates inferiorly with gravity, donor-zone wound healing (linear suture line for FUT, dot puncture wounds for FUE), and graft anchorage progressing from fragile to secure.

Day Recipient zone Donor zone Edema Activity Wash
0 (surgery) Pinpoint bleeding stops within hours; small crusts begin forming. FUT: sutured/stapled strip with pressure dressing. FUE: open dot wounds. None yet. Sleep semi-upright (30–45°). No bending or lifting. Saline mist every 30–60 min while awake to keep grafts hydrated.
1–2 Crusts visible at each graft; recipient skin pink to bright red. Dressing typically off at 24 h; donor area tender. Forehead/eyelid edema appears day 1–2, peaks day 2–4. Often dramatic, benign. Walking allowed; no exercise. Frontal headband day 0–4 cuts edema migration. Gentle rinses at 24–48 h: warm water poured (not sprayed); no scrubbing. Saline spray continues.
3–4 Crust fully formed; redness prominent; itching may begin. Suture/staple line firm; FUE dots crusted. Edema peaks; often spreads to bridge of nose and periorbital region. Sedentary work feasible; no aerobic activity. Begin gentle baby-shampoo wash. Lather in the palm and dab onto grafts — no fingertip rubbing.
5–7 Crusts loosening at edges; erythema fading toward pink. Donor itching common as healing progresses. Resolves by day 5–7. Light walking; many return to desk work. Daily gentle shampoo; saline spray tapered.
8–10 Most crusts shed with gentle washing; some persist. FUT: sutures/staples removed day 10–14. — Some surgeons clear light cardio at day 10. Weights deferred to week 3+. Graft anchorage near baseline by day 9 — more normal washing pressure permitted.
11–14 Recipient zone faintly pink, mostly clean. Transplanted hairs about to enter shedding. FUT scar still red and raised; FUE dots pink. — Gentle exercise resumed; no submersion swimming, sauna, or contact sports yet. Resume normal shampoo and conditioner.

Surgeon-specific variation is substantial — first-wash timing ranges from 24 to 72 hours across major clinics, and pressure-cap protocols differ. These reflect tradition more than head-to-head trial data.

Don't pick at crusts

Premature graft avulsion has been documented at up to day 7–9 with sufficient force. If a crust hasn't released by day 14, soak it off with a damp warm towel held against the scalp for 5–10 minutes, then gently wash. Picking, scratching, or scrubbing risks pulling a graft out along with the crust.

Shock loss and the shedding phase

Transplanted follicles undergo transient ischemia and surgical trauma during extraction and placement. This forces them out of anagen into catagen and then telogen. The follicle bulb survives; the existing hair shaft is shed. Most sources quote 70–100% of grafts shedding between weeks 2 and 6. A minority (5–30%) skip the shed and continue growing without a visible gap — these are distinguishable in early photos but don't predict superior final density.

A separate phenomenon is shock loss of native, non-transplanted hairs in or adjacent to the recipient zone. The mechanism is post-traumatic telogen effluvium of pre-existing miniaturized or borderline-anagen hairs, triggered by the inflammatory and vascular insult of recipient-site creation. Reported incidence in cis-male AGA cohorts is 5–30%, higher when transplanting into densely populated existing hair, in older patients, and with denser packing. Most native shock loss reverses with regrowth at 3–6 months. In patients with active progressive AGA, some lost native hairs may not return.

The dormancy period between shedding and regrowth is 6–14 weeks. The recipient zone often looks thinner than it did preoperatively during this window, especially if native shock loss occurred. This is the "ugly duckling stage" in patient communities and is the single phase most associated with regret and panic emails to surgeons.

For transfeminine patients on stable HRT, native shock loss is probably lower than in cis-male AGA cohorts because progressive androgen-driven loss is suppressed by anti-androgens and estrogen prolongs anagen. This is inference, not a measured number — the literature hasn't been done.

The 3–12 month growth curve

Regrowth follows a remarkably consistent S-curve across published series. Individual variation is wide; the figures below are population averages.

Postop month Approx. % of grafts visibly regrowing What you see
3 10–30% First "spiky" terminal hairs emerging through scalp; texture wiry/curly initially.
4 30–50% Visible thickening; many hairs short and fine.
6 50–70% Roughly half the final result visible; styling possible; pink discoloration usually gone.
8 70–85% Density approaches final; caliber still maturing.
12 85–95% Cosmetic result mostly judged here, though some grafts still emerging.
15–18 ~100% Full caliber, color, and curl pattern of mature hair.

Modifiers worth knowing about:

  • Recipient zone. Temple and crown grafts emerge slightly later than frontal hairline grafts in some series.
  • Hair caliber and curl. Coarser, curlier hair gives apparent density faster; fine straight hair appears thinner at any given month.
  • Concurrent therapy. Continued minoxidil and 5-ARI use thickens native hair in the same field, which can confound assessment of graft yield.

Long-term graft survival in well-executed FUE and FUT exceeds 90% at 1 year, with several series showing essentially permanent retention thereafter because occipital donor follicles are largely DHT-resistant. Long-term graft survival in transfeminine patients on chronic estrogen has not been formally measured; the working assumption is that survival is at least as good as in cis-female cohorts.

Wound care and topical regimens

Two recurring goals: graft hydration (prevents desiccation and supports anchoring) and gentle crust removal (without dislodging grafts).

  • Saline spray. Sterile mist every 30–60 min during waking hours for the first 2–3 days is near-universal. Frequency tapers after.
  • First wash. Most modern protocols permit gentle rinsing at 24–48 h and full shampooing by day 3–5. Lather shampoo in the palm and dab onto grafts — no fingertip rubbing for the first 9–10 days.
  • Crust removal. By day 7–10 most crusts release with washing. Persistent crusts at day 14 soak off with a damp warm towel held against the scalp for 5–10 min, then gentle wash. Picking is contraindicated.
  • Resuming normal shampoo. Around day 14. Sulfate-based products aren't contraindicated, but many people prefer gentler formulations through the first month.
  • Sun protection. UV exposure to the recipient zone worsens erythema and can cause postinflammatory hyperpigmentation, especially in skin types III–VI. Hat or SPF 30+ for 3–6 months on both donor and recipient zones. The FUT scar hyperpigments easily if exposed early.

Activity restrictions

The biomechanical concern is graft displacement by shear or by sweat-mediated edema in the first 7–10 days, plus donor-wound dehiscence (FUT) over weeks 2–3. Graft anchorage strength reaches near-baseline by day 9 in mechanical studies; everything else is extrapolation.

Activity Earliest typical resumption Why
Sedentary work Day 3–5 Anchorage adequate for non-physical activity.
Light walking Day 1 Minimal shear.
Sleeping flat (vs. 30–45° elevated) Day 7–10 Reduces edema risk.
Sleeping prone / face-down Avoid 2–4 weeks Direct shear on recipient zone.
Light cardio (jog, stationary bike) Day 10–14 Sweat tolerance and graft anchorage.
Heavy resistance training Week 3–4 Valsalva spikes scalp BP; FUT donor wound tension.
Submersion swimming (chlorine/salt) Week 3–4 Wound contamination; chlorine irritation.
Sauna, steam room, hot tub Week 4–6 Vasodilation, edema, contamination.
Loose hat (non-friction) Day 5–7 Tight or pulled-on hats shear grafts before week 2.
Helmets, hard hats, tight beanies Week 3–4 Direct mechanical shear.
Hair styling product Week 2–3 Avoid until crusts resolved.
Coloring, perming, chemical relaxers Week 4–6 minimum, often longer Chemical irritation of healing scalp.

Concomitant medical therapy

  • Minoxidil. Most clinics pause topical minoxidil 1–2 weeks pre-op and restart at 2–4 weeks post-op. Earlier risks scalp irritation; later allows additional native shedding. Oral minoxidil (low-dose, 0.25–2.5 mg) is often continued through the perioperative period without pause; ask your surgeon's specific protocol.
  • Finasteride / dutasteride. Continuation through the perioperative period is standard and reduces native shock loss in cis-male protocols. For transfeminine patients these are usually being used as anti-androgens for HRT rather than for AGA specifically — same logic, default is to continue.
  • Spironolactone. No evidence of negative interaction with healing. Continue.
  • Estrogen. No published evidence of adverse effect on graft survival. The perioperative VTE concern hasn't borne out in the FFS literature (953-patient cohort, no excess VTE on continued estrogen). Decisions individualized with the anesthesia team, but routine stop is not justified.
  • PRP (platelet-rich plasma). Adjunct PRP at surgery and during recovery has been studied as a way to accelerate regrowth. Meta-analyses report modest improvement (roughly 5–15% density gain at 6 months) with high heterogeneity in protocols. Not standard-of-care; offered as an upgrade by many clinics.

Donor-area recovery

FUT linear scar. Standard surgical wound-healing trajectory: erythema and induration peak at 2–4 weeks, tensile strength reaches ~80% of baseline by 6–8 weeks, scar maturation (fading, thinning) continues through 12 months. Trichophytic closure (overlapping the upper edge so hairs grow through the scar) reduces visible scar width. Reported widened-scar rates: 2–15%, depending on closure technique, scalp laxity, and revision history.

FUE dot scars. Each 0.8–1.0 mm punch leaves a circular dot. By 3–6 months these are typically invisible to casual inspection at conversational distance but remain visible under trichoscopy or with very short clipper lengths. Hypopigmentation of dot scars is common in skin types IV–VI and may be permanent. Visible dot density at clipper grade 1–2 is the practical limit on minimum hairstyle length post-FUE — rarely an issue for transfeminine patients planning longer hair.

Donor effluvium. A minority of patients experience telogen effluvium of the donor zone itself: patchy thinning around the harvest area at 6–12 weeks. Usually resolves by 6 months. Incidence poorly quantified (~1–3% in surgeon experience reports).

Things that are normal and panic-inducing

  • "My new hair is shedding — did the surgery fail?" Expected shock loss at weeks 2–6. Bulb survives.
  • "My forehead is swollen and I look puffy." Edema peaking day 2–4 is universal and migrates inferiorly to the eyelids and bridge of the nose by day 4–5.
  • "My recipient zone is bright pink/red." Erythema persists 2–8 weeks, longer in fair skin. Not infection unless tender, warm, purulent, or febrile.
  • "Small pimples among the new hairs at month 3–5." Folliculitis from hairs erupting through scalp; usually resolves with warm compresses or short topical antibiotic.
  • "My hair texture is wiry/curly and a different color." Newly emerging hairs often kink and lighten temporarily; mature texture appears by 9–18 months.
  • "It looks worse at month 2 than before surgery." Dormancy plus native shock loss. The ugly-duckling phase.

When to call the surgeon

Several findings warrant prompt contact rather than waiting for routine follow-up.

Finding Concern
Fever > 38 °C, expanding erythema, purulent discharge, severe local pain Wound infection (uncommon, <1%); needs antibiotics ± drainage.
Sudden focal bleeding from a graft site after day 1 Possible graft displacement; pressure 10–15 min, call if persists.
A graft visibly knocked out (tiny plug on pillowcase) before day 9 Report — usually not replaceable, but informs aftercare.
Severe persistent pain not controlled by prescribed analgesics Hematoma, infection, or nerve entrapment.
FUT donor dehiscence (staples/sutures pulling apart) Needs re-closure.
Pustular folliculitis with fever or rapid spread Bacterial superinfection.
Numbness persisting > 6 months in donor or recipient zone Sensory nerve injury; usually resolves but worth documenting.
No regrowth by month 8–9 Worth assessment, though final judgment is deferred to month 12.

Long-term assessment and revision

Most experienced practices defer final cosmetic assessment to 12 months, with re-assessment for revision or touch-up grafting at 12–18 months. Reasons to revise: areas of low-density yield, hairline shape that didn't meet expectations, native loss progression revealing thinning behind the transplant, or simply wanting more density on a second pass. Re-grafting before 12 months risks misjudging final density because not all grafts have matured.

Long-term follow-up is also when patients with progressive AGA decide on ongoing medical therapy to protect the non-transplanted native hair behind and around the graft zone. Without it, native loss can progress and create an unnatural "island" of transplanted density — a classic cause of late dissatisfaction in cis-male cohorts. For transfeminine patients on chronic anti-androgen therapy this risk is substantially lower but not zero, particularly if HRT was started after substantial AGA had already occurred.

Open questions

The recovery literature has notable gaps. Comparative trials of aftercare protocols barely exist — first-wash timing, saline frequency, sleep angle, and activity windows are clinic preferences with little head-to-head evidence. Transfeminine-specific data on graft survival, regrowth velocity, and shock loss rates under chronic estrogen and anti-androgen therapy are not published; recommendations are extrapolated from cis-female cohorts. Long-term (>5 year) graft survival under HRT has not been quantified.

Most quantitative figures on this page (shed percentages, regrowth curves, shock-loss incidence) come from cis-male AGA cohorts. The aesthetic timeline (12–18 months) and day-by-day course are likely transferable; the population-specific risk of progressive native loss during recovery is probably lower in transfeminine patients on stable HRT, though precise numbers are absent.

Sources